Abbott Laboratories (FRA:ABL)
Germany
· Delayed Price · Currency is EUR | Market Cap | 198.54B |
| Revenue (ttm) | 39.18B |
| Net Income (ttm) | 12.44B |
| Shares Out | n/a |
| EPS (ttm) | 7.13 |
| PE Ratio | 15.95 |
| Forward PE | n/a |
| Dividend | 2.10 (1.86%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 47 |
| Average Volume | 422 |
| Open | 114.26 |
| Previous Close | 113.00 |
| Day's Range | 113.56 - 114.26 |
| 52-Week Range | 91.68 - 133.78 |
| Beta | n/a |
| RSI | 46.39 |
| Earnings Date | Jul 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news
Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b...
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while staying poised to outperform.
Abbott Labs is a textbook recession play, says Jim Cramer
'Mad Money' host Jim Cramer checks in on Abbott Labs.
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
Abbott Laboratories (NYSE: ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday. Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over ye...
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.
US Stocks Likely To Open Higher Ahead Of Festive Weekend: 'Current Equity Levels Offer An Attractive Entry Opportunity'
U.S. stock futures rose on Thursday ahead of the long weekend, with Good Friday falling on April 18 and Easter Sunday on April 20. Futures of major benchmark indices were higher in premarket. Federal ...
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2163744801-84829cb23f204afc82fcad1ccf25626f.jpg)
Abbott Labs Stock Jumps on Strong Earnings, With $500M Investment in US Facilities
Abbott Laboratories shares surged Wednesday after the medical device maker said it plans to invest $500 million in U.S. operations and topped Wall Street’s expectations with its first-quarter results.
Abbott Labs shares surge on earnings and a big sign of confidence in the business
Abbott's strong stock performance continued Wednesday after a first-quarter earnings beat and a guidance reaffirmation.
Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript
S&P 500 (NYSEARCA: SPY) Live: JBHT (Nasdaq: JBHT) Falls, ABT (NYSE: ABT) Rises on Tariff Fallout
Live Updates Live Coverage Updates appear automatically as they are published. Earnings Growth 11:16 am by Gerelyn Terzo The S&P 500 is now lower by less than 1% on the day, off of its worst levels of...
Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday. The Dow traded down 0.67% to 40,099.73 while the NASDAQ dipped 2.12% to 16,466.96. The S&P 500 also fell,...
Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.
Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty
Abbott Laboratories (NYSE: ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion . First-quarter sales increase...
Abbott Laboratories Dips As Sales Come In Light Despite Profit Beat
Abbott stock slipped early Wednesday after the health giant reported light first-quarter sales, though profit beat expectations.
Abbott Labs Profit Jumps on Gains in Nutrition, Medical Devices
Abbott Labs Profit Jumps on Gains in Nutrition, Medical Devices
Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.
Abbott Laboratories Stock Slips as First-Quarter Sales Miss Expectations
Abbott Labs stock slips on Q1 sales miss
Earnings Snapshot: Abbott Laboratories Q1 earnings beat; revenue misses estimate; reaffirms FY outlook
Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights
Abbott Laboratories (NYSE: ABT) reported its first quarter 2025 earnings results today. Total sales increased 4% year-over-year to $10.35 billion. Organic sales growth was 6.9%. Net earnings grew 8.2%...
Abbott in charts: Medical Devices sales up 10% Y/Y in Q1, down 3% sequentially
More on Abbott Laboratories Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees Abbott Laboratories Basking In A Sharp Turn In...